Reuters reveals Illumina in talks with EU regulators to divest Grail


Reuters exclusively reported that U.S. life sciences company Illumina is in talks with European Union (EU) antitrust regulators to divest Grail ahead of an expected EU veto of its $7.1 billion acquisition of the biotechnology company. The European Commission confirmed the Reuters story the next day and blocked the deal because remedies offered by Illumina did not fully address the EU competition enforcer’s concerns.

Article Tags

Topics of Interest: Technology

Type: Reuters Best

Sectors: Business & Finance

Regions: Europe

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text


Leave a Comment